✦ LIBER ✦

Lipid biomarkers, hormone therapy and the risk of venous thromboembolism in women

✍ Scribed by B. M. EVERETT; R. J. GLYNN; J. E. BURING; P. M RIDKER

Book ID: 109152859
Publisher: John Wiley and Sons
Year: 2009
Tongue: English
Weight: 112 KB
Volume: 7
Category: Article
ISSN: 1538-7933
DOI: 10.1111/j.1538-7836.2009.03302.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Hormone replacement therapy and risk of

Hormone replacement therapy and risk of venous thromboembolism – still unresolved questions

✍ P. M. SANDSET 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 70 KB

Hormone replacement therapy and the risk

Hormone replacement therapy and the risk of venous thromboembolism: a population-based study

✍ C. RENOUX; S. Dell'ANIELLO; S. SUISSA 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 146 KB

Hormonal factors and risk of recurrent v

Hormonal factors and risk of recurrent venous thrombosis: the Prevention of Recurrent Venous Thromboembolism trial

✍ M. CUSHMAN; R. J. GLYNN; S. Z. GOLDHABER; S. MOLL; K. A. BAUER; S. DEITCHER; S. 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 497 KB

Obesity and risk of venous thromboemboli

Obesity and risk of venous thromboembolism among postmenopausal women: differential impact of hormone therapy by route of estrogen administration. The ESTHER Study

✍ M. CANONICO; E. OGER; J. CONARD; G. MEYER; H. LÉVESQUE; N. TRILLOT; M. T. BARREL 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 178 KB

Risk of pregnancy-associated recurrent v

Risk of pregnancy-associated recurrent venous thromboembolism in women with a history of venous thrombosis

✍ I. PABINGER; H. GRAFENHOFER; A. KAIDER; P. A. KYRLE; P. QUEHENBERGER; C. MANNHAL 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 138 KB

The risk of venous thromboembolic diseas

The risk of venous thromboembolic disease associated with adjuvant hormone therapy for breast carcinoma : A systematic review

✍ Steven R. Deitcher; Marcelo P. V. Gomes 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 110 KB 👁 1 views

## Background: Tamoxifen therapy for patients with breast carcinoma is perceived as an independent risk factor for venous thromboembolic events (vte), but the risk associated with other adjuvant therapies is less well recognized. ## Methods: The authors conducted a computerized pubmed literature